Are peptides legal in Australia?

Some peptides are registered medicines, many are prescription only, and a handful carry a possession offence. Two separate layers of law decide which applies to a given vial.

The first layer is scheduling. The Poisons Standard is made under the Therapeutic Goods Act 1989 and sorts substances into Schedules. Its own introduction says the classifications are recommendations that States and Territories implement through their own legislation, and that for legal definitions "it is necessary to check with each relevant State or Territory authority". ^[1] Schedule 4 covers substances whose use or supply should be by or on the order of a person permitted to prescribe, available from a pharmacist on prescription. ^[1]

The second layer is therapeutic goods regulation. The TGA says peptide products regulated as therapeutic goods must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be imported, manufactured, supplied, exported or advertised, with limited exceptions. Products outside the ARTG are "unapproved". ^[2]

State penalties show what the first layer means in practice. A criminal lawyer quoted by the Law Society Journal in July 2026 said that in NSW, possessing or attempting to possess these peptides without a valid prescription carries a maximum penalty of $2,200 and/or 6 months' imprisonment, and unlawful supply carries up to $2,200 and/or 2 years. ^[4] Other states set their own penalties.

Thirteen compounds in our range are Schedule 4 in the June 2026 Poisons Standard (instrument F2026L00633, in force from 1 June 2026). We checked all 28 against the full instrument text and the WADA 2026 Prohibited List on 29 September 2026. ^[1][3]

"S0 may apply" means the compound is not named, and we could not confirm whether it holds governmental approval for human therapeutic use anywhere, which is the test S0 uses. Sport Integrity Australia can answer that for a specific substance.

How to read a Schedule 4 entry yourself

Take CJC-1295 as the worked example. Search the instrument text on legislation.gov.au for the name and you find the Schedule 4 line "# CJC-1295 (CAS No. 863288-34-0)". Note 2 at the top of Schedule 4 says "Substances marked # are listed in Appendix D", and Appendix D clause 5, item 7, repeats the entry under the heading "Poisons for which possession without authority is illegal". ^[1]

Three details catch people out:

1. CAS numbers differ between sources. The entry cites CAS 863288-34-0. The PubChem record we use for CJC-1295 identifiers carries CAS 446262-90-4. Search by name and by every CAS number you hold.
2. Qualifiers change the scope. Glutathione is Schedule 4 "for parenteral use", and human chorionic gonadotrophin is Schedule 4 "except in pregnancy test kits". ^[1]
3. Group entries catch unnamed compounds. Tesamorelin has no line of its own, but Schedule 4 and Appendix D both carry "growth hormone releasing hormones (GHRHs)". Copper compounds for human use are Schedule 4 with exceptions, which is why GHK-Cu stays unresolved in our table. ^[1] Where a group entry is the only match, confirm with the TGA.

Approved peptide medicines are specific products entered on the ARTG. The TGA's examples are insulin and insulin analogues, GLP-1 receptor agonists such as semaglutide, oxytocin, vasopressin analogues such as desmopressin, and somatostatin analogues such as octreotide. ^[2] Sport Integrity Australia lists insulin, semaglutide, somatropin and vasopressin as common registered peptide medicines. ^[5]

Approval belongs to the registered product. A vial of semaglutide from a research supplier sits outside the ARTG even though the compound appears in registered medicines. The TGA names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products. ^[6]

Some peptide products are regulated as cosmetics instead. The TGA says this applies where a product's ingredients, claims, presentation and intended use are limited to cosmetic purposes. ^[7]

"Research use only" is a supplier's statement of intended use: laboratory work, with no human or veterinary use. It describes the sale. The law looks at the product itself.

The TGA puts it plainly. Disclaimers that a product is for "research use only" or "not for human use" do not change whether it is regulated as a therapeutic good, and they do not remove advertising, manufacture, import, export or supply obligations. ^[2] Its April 2026 safety alert adds that such disclaimers do not make supply lawful or permit importation. ^[6]

The Poisons Standard has a narrow provision of its own. Poisons packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from its labelling requirements, and the instrument states that this exemption does not extend to controls on supply. ^[1] Peptides Collective sells compounds for laboratory research use only and publishes no human-use information.

Only where a valid exemption, approval or authority applies. That is the TGA's position for unapproved peptide products, and it adds that the Personal Importation Scheme does not allow commercial supply or public advertising. ^[2]

The TGA and the Australian Border Force work together at the border. Imports that appear unlawful may be seized and destroyed, and the buyer loses the goods and the money. ^[2] The TGA's May 2026 warning says products that are poorly labelled, marked only with codes, or missing the name and concentration of the active ingredient will not be released under the scheme. ^[8]

For prescription-restricted peptides, the conditions described in the Law Society Journal include personal or immediate-family use only, a valid Australian prescription at the time of importation, and quantity caps of three months' supply per import and 15 months' supply in any 12 months. The same article says unauthorised importation from overseas suppliers is a Commonwealth offence carrying imprisonment of up to five years. ^[4]

Many are. WADA class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the List and without current approval by any governmental regulatory health authority for human therapeutic use, and it names BPC-157 as an example. ^[3] Class S2 prohibits peptide hormones, growth factors, related substances and mimetics at all times, naming AOD-9604, CJC-1295, ipamorelin, tesamorelin and kisspeptin among others. ^[3]

Sport Integrity Australia lists BPC-157, CJC-1295, ipamorelin, MOTS-c and thymosin beta-4 (TB-500) as common prohibited examples. It warns that possession or use can lead to an anti-doping rule violation, and that a Therapeutic Use Exemption is unlikely for an unregistered medicine. ^[5] The 2026 List took effect on 1 January 2026. ^[3] Check any substance against the current edition on Global DRO, the checker Sport Integrity Australia points athletes to. ^[5]

Enforcement has stepped up through 2026. The dates below come from the instruments and regulator pages themselves.

The ABC reported in June 2026 that the TGA's response may include product seizures, infringement notices and civil or criminal penalties, and that the TGA, Border Force and Victoria Police had seized peptides and other drugs with an estimated street value of more than $2 million. ^[10] The TGA has also said it is working with social media and e-commerce platforms to remove unlawful advertising. ^[9]

Regulators report adverse events and quality failures, and product-testing studies back up the quality concerns. Adverse events and concerns received by the TGA include severe allergic reactions requiring adrenaline and hospitalisation, systemic inflammatory response syndrome, full-body itching, blurred vision, extreme tiredness, musculoskeletal injuries and unsealed packaging from an online supplier. ^[6] These are reports received by a regulator. They do not establish cause or frequency.

Laboratory studies show why a label alone proves little:

• Content and purity. A 2024 study bought semaglutide vials from online sellers operating without prescriptions. Measured content exceeded the label by 28.56% to 38.69%, purity measured 7.7% to 14.37% against 99% claimed on labels, and endotoxin was detected in every sample (PMID 39509151). ^[11]
• Blind spots in routine testing. A 2020 study found undeclared mannitol at 20% and 43% w/w in two commercially sourced custom synthetic peptides. The authors note that LC-based quality control can be "blind" to certain impurities, including UV-transparent ones (PMID 31671336). ^[12]
• Black-market seizures. The Cologne anti-doping laboratory analysed 337 black-market products between 2010 and 2013; 12.8% were peptide hormones and growth factors, and thymosin beta-4 was among the findings (PMID 25168622). ^[13]

Run five checks. The first three settle legal and sport status, the last two settle what is in the vial.

Peptide quality testing uses separate methods for separate questions. United States Pharmacopeia scientists describe NMR, mass spectrometry and chromatography for identity, and HPLC and GC methods for peptide content and impurities (PMID 36949371). ^[14] Peptide drugs often occur as salts with counter-ions (PMID 33287352). ^[15] The counter-ion adds weight to the powder, which is one reason net peptide content is reported separately from purity.

At Peptides Collective, every batch is tested by an independent lab before sale for purity by HPLC and identity by mass spectrometry. The certificate is published under the batch number printed on the vial, and you can search it in our certificate of analysis library. Our testing page describes the process, and the guide on how to read a peptide certificate of analysis explains the trace and the spectrum.

A worked example: BPC-157 has a molar mass of 1419.5 g/mol for the 15-residue sequence GEPPPGKPADDAGLV, per PubChem. The identity result on a BPC-157 certificate should match that mass, and the batch number should match the vial. The BPC-157 product page links the current batch certificate, and our BPC-157 explainer covers what the research literature contains. That same compound is Schedule 4 and Appendix D, so the certificate answers the content question only.

Australian peptide law runs compound by compound across two layers: the Poisons Standard, which state law adopts, and the TGA's rules for therapeutic goods. Thirteen of our 28 research compounds are Schedule 4 and seven carry a possession offence, while an unnamed compound can still be an unapproved therapeutic good. A "research use only" label changes none of this. A batch certificate verifies what is in a vial, and the Poisons Standard, the TGA and the WADA List govern everything else.